TCHP and prostate cancer: In this study we observed a reduction in Mitostatin expression in two prostatecancer-derived cell lines (1542CP3TX and 1532CP2TX; 16.7% ofthe cancer-derived cell lines) and in ∼35% of a series of 124 prostate cancers.